Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates
- Revvity (RVTY) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.22 per share a year ago.
- 07/28/2025
|
Revvity trims 2025 profit forecast on soft demand for diagnostics in China
- Medical equipment maker Revvity on Monday lowered its full-year adjusted profit forecast as it expects demand for its diagnostics products in some international markets to remain soft, sending the company's shares down 8% premarket.
- 07/28/2025
|
Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.
- The health sciences company posts better-than-expected adjusted earnings and revenue but trims its guidance.
- 07/28/2025
|
Revvity Q2 Revenue Up 4 Percent
- Revvity Q2 Revenue Up 4 Percent
- 07/28/2025
|
Revvity Announces Financial Results for the Second Quarter of 2025
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operati.
- 07/28/2025
|
Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again
- Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/25/2025
|
Revvity Board Declares Quarterly Dividend
- WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from disc.
- 07/24/2025
|
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
- RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
- 07/24/2025
|
Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings
- Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
- 07/23/2025
|
Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/21/2025
|
Revvity to Hold Earnings Call on Monday, July 28, 2025
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of t.
- 07/07/2025
|
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requi.
- 06/02/2025
|
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
- Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
- 05/23/2025
|
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 in.
- 05/19/2025
|
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
- Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the company maintained full-year guidance. While I rate Revvity a buy, it faces some structural challenges longer-term.
- 05/09/2025
|
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
- Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
- 04/28/2025
|
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
- Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
- 04/28/2025
|
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
- While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 04/28/2025
|
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
- Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.
- 04/28/2025
|
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
- Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.
- 04/28/2025
|
Revvity beats quarterly estimates on steady demand for medical equipment
- Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for drug research.
- 04/28/2025
|
Revvity Announces Financial Results for the First Quarter of 2025
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operati.
- 04/28/2025
|
Why Revvity (RVTY) Could Beat Earnings Estimates Again
- Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/25/2025
|
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
- RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
- 04/25/2025
|
Revvity Board Declares Quarterly Dividend
- WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery.
- 04/24/2025
|
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline
- Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/21/2025
|
Revvity to Hold Earnings Call on Monday, April 28, 2025
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of t.
- 04/03/2025
|
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
- RVTY's strong product portfolio raises optimism about the stock.
- 04/02/2025
|
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster hig.
- 04/02/2025
|
Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery
- WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle. The Signals One platform addresses the growing complexity of drug modalities research by delivering a complete solution that integrates advanced research capabilities a.
- 04/02/2025
|
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
- RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
- 03/21/2025
|
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.
- 03/20/2025
|
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
- WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operat.
- 02/20/2025
|
Revvity to Present at Upcoming Investor Conferences
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Conference Monday, March 3, 2025 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 45th Annual Health Care Conference Tuesday, March 4, 2025 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Leerink Partners Global Healthcare Conference Tuesday, M.
- 02/20/2025
|
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
- DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
- 02/13/2025
|
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
- Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
- 01/31/2025
|
Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 01/31/2025
|
Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript
- Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Luke Sergott - Barclays Andrew Cooper - Raymond James Catherine Schulte - Baird Dan Brennan - TD Cowen Operator Hello, everyone, and welcome to Revvity's Fourth Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today.
- 01/31/2025
|
Revvity (RVTY) Surpasses Q4 Earnings Estimates
- Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago.
- 01/31/2025
|
Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending
- Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research.
- 01/31/2025
|
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $119 million, as compared to $77 million f.
- 01/31/2025
|
Revvity Gears Up for Q4 Earnings: What's in the Offing?
- RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
- 01/29/2025
|
Revvity (RVTY) Earnings Expected to Grow: Should You Buy?
- Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/24/2025
|
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
- Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/23/2025
|
Revvity Ignites Scientific Breakthroughs at SLAS2025
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity's Harmony™ and Signals Image Artist™ software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis. This significant advancement expand.
- 01/23/2025
|
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test
- Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.
- 01/13/2025
|
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this reg.
- 01/12/2025
|
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
- RVTY's strong product portfolio raises optimism about the stock.
- 12/31/2024
|
Revvity to Present at J.P. Morgan Healthcare Conference
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and.
- 12/17/2024
|
Safe Biopharma: Revvity's Recurring Revenues And Diagnostics
- Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) from consumables, services, and software ensures predictable income and financial stability. The company has a global footprint and an estimated TAM exceeding $60 billion, showcasing its significant market opportunity.
- 12/16/2024
|
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
- Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
- 12/04/2024
|
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fi.
- 11/20/2024
|
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
- Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.
- 11/05/2024
|
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
- Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
- 11/04/2024
|
Revitty (RVTY) Q3 2024 Earnings Call Transcript
- Revitty Incorporated (NYSE:RVTY ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice President, Chief Financial Officer Steve Willoughby - Head of Investor Relations Conference Call Participants Mike Ryskin - Bank of America Vijay Kumar - Evercore ISI Dan Leonard - UBS Andrew Cooper - Raymond James Luke Sergott - Barclays Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Dan Arias - Stifel Matt Sykes - Goldman Sachs Brandon Couillard - Wells Fargo Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Hello everyone and welcome to Revitty's third quarter 2024 earnings conference call. My name is Lydia and I will be your Operator today.
- 11/04/2024
|
Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings
- Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/04/2024
|
Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates
- Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago.
- 11/04/2024
|
Revvity cuts 2024 revenue forecast amid biotech spending slowdown
- Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development.
- 11/04/2024
|
Revvity Announces Financial Results for the Third Quarter of 2024
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $98 million, as compared to $69 million for the same period a year ago. GAA.
- 11/04/2024
|
Revvity to Report Q3 Earnings: What's in Store for the Stock?
- RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.
- 11/01/2024
|
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline
- Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/28/2024
|
Revvity Board Declares Quarterly Dividend
- WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fro.
- 10/24/2024
|
Revvity Shares Decline Despite Launch of Transcribe AI Solution
- RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
- 10/23/2024
|
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company's sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity's continued evolution and strengthened commitments to creating a lasting, positive impact on the world. “Whether it's from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste a.
- 10/22/2024
|
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
- Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
- 10/10/2024
|
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
- RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.
- 10/07/2024
|
Reasons to Retain Revvity Stock in Your Portfolio for Now
- RVTY's strong product portfolio raises optimism about the stock.
- 09/06/2024
|
MD or RVTY: Which Is the Better Value Stock Right Now?
- Investors interested in Medical Services stocks are likely familiar with Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?
- 08/26/2024
|
MD or RVTY: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?
- 08/09/2024
|
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
- Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
- 07/29/2024
|
Diagnostic Products Demand Boosts Profit and Sales at Revvity
- Revvity (RVTY) shares advanced Monday after the medical equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidance on higher demand for its diagnostic products.
- 07/29/2024
|
Revvity, Inc. (RVTY) Q2 2024 Earnings Call Transcript
- Revvity, Inc. (NYSE:RVTY ) Q2 2024 Earnings Conference Call July 29, 2024 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President & CEO Max Krakowiak - SVP & CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Catherine Schulte - Baird Luke Sergott - Barclays Michael Ryskin - Bank of America Paul Knight - KeyBanc Rachel Vatnsdal - JP Morgan Tycho Peterson - Jefferies Operator Hello, and welcome to the Q2 2024 Revvity Earnings Conference Call. My name is Elliott, and I'll be coordinating your call today.
- 07/29/2024
|
Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Revvity (RVTY) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 07/29/2024
|
Revvity raises 2024 profit forecast on medical equipment demand; shares rise
- Medical equipment maker Revvity raised its annual profit forecast on Monday, after beating second-quarter results estimates on better-than-expected demand for its diagnostic products.
- 07/29/2024
|
Revvity (RVTY) Tops Q2 Earnings Estimates
- Revvity (RVTY) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.21 per share a year ago.
- 07/29/2024
|
Revvity Announces Financial Results for the Second Quarter of 2024
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP op.
- 07/29/2024
|
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
- Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/22/2024
|
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
- Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/19/2024
|
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
- Revvity's (RVTY) strong product portfolio raises optimism about the stock.
- 07/03/2024
|
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
- Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE: RVTY) under which Revvity will market and commercialize Bionano's VIA™ software as part their newborn sequencing research workflow. VIA is expected to enhance the comprehensive reporting capabilities of Revvity's sequencing solution by adding an assessment of CNVs to its NGS workflow and streamlining the workflow's interpretation capabilities.
- 06/20/2024
|
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
- Revvity's (RVTY) strong product portfolio raises optimism about the stock.
- 05/30/2024
|
Revvity to Present at Goldman Sachs Global Healthcare Conference
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company's website at www.revvity.com. A replay of the presentation will be posted on the Revvi.
- 05/28/2024
|
Lab Instrument Industry Update - New Commercial Entrants
- Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
- 05/23/2024
|
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
- Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.
- 04/29/2024
|
Revvity (RVTY) Reports Q1 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 04/29/2024
|
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
- Revvity (RVTY) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.01 per share a year ago.
- 04/29/2024
|
Revvity beats quarterly estimates on demand for diagnostic equipment
- Revvity on Monday beat Wall Street estimates for its quarterly profit and revenue, helped by better-than-expected demand for equipment in its diagnostics unit.
- 04/29/2024
|
Revvity Announces Financial Results for the First Quarter of 2024
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024. The Company reported GAAP earnings per share of $0.21, as compared to $4.50 in the same period a year ago. GAAP revenue for the quarter was $650 million, as compared to $675 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $44 million, as compared to $76 million for the same period a year ago. GAAP op.
- 04/29/2024
|
Revvity Board Declares Quarterly Dividend
- WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discover.
- 04/25/2024
|
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
- Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
- 04/25/2024
|
Revvity to Present at BofA Securities 2024 Health Care Conference
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company's website at www.revvity.com. A replay of the presentation will be posted on the Re.
- 04/25/2024
|
Revvity Unveils a New Era of Automated Tuberculosis Testing
- WALTHAM, Mass.--(BUSINESS WIRE)-- #TB--Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution. “The ability to use the Auto-Pure 2400.
- 04/24/2024
|
Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up
- Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.
- 04/16/2024
|
Revvity Signals Software's New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners
- WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, will launch Signals SynergyTM, a software solution designed to drive greater collaboration, project management, and data exchange between pharmaceutical and biotechnology sponsors with their external contract partners. Addressing the challenge of relying on email or file-sharing platforms to report complex scientific findings, Signals Synergy expands its Sign.
- 04/15/2024
|
Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?
- Revvity (RVTY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 04/10/2024
|
Revvity To Hold Earnings Call on Monday, April 29, 2024
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or.
- 04/04/2024
|
Preliminary Injunction Granted to Enforce Revvity's Rights and Cloud Software Group's Obligations Related to Spotfire Software
- WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has granted a preliminary injunction compelling Cloud Software Group (CSG) to comply with its contractual obligations under its strategic partner agreements with Revvity, including an order to cease all marketing, selling and support activities in Revvity's exclusive markets and to continue delivering maintenance services to Revvity in relation to its Spotfire® software. This decis.
- 04/02/2024
|
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
- Revvity's (RVTY) strong product portfolio raises optimism about the stock.
- 04/01/2024
|
Revvity's (RVTY) New Launch to Boost Research Productivity
- Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
- 03/21/2024
|
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
- WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that it has filed a complaint against Cloud Software Group (CSG) in Massachusetts Superior Court and requested injunctive relief to enforce Revvity's rights and CSG's obligations as a strategic partner. CSG is refusing to honor its contractual obligations with Revvity as a strategic partner, including violating the terms of its agreements with Revvity for its TIBCO Spotfire® software. In addition, CSG is interfering in.
- 03/20/2024
|
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
- Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
- 03/18/2024
|
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
- WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, the latest advancement in the Revvity Signals Software portfolio. This innovative chemistry suite is set to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, as well as academia, develop and communicate complex chemical concepts and collaborate across dis.
- 03/18/2024
|
Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab's needs. “This new workflow from Revvity seeks to elevate the customer experience by leveraging a rich variant database for newborn sequencing research and providing critical components necessary to be able to go from sample to result,” said Madhuri Hegde, PhD, FACMG.
- 03/15/2024
|
Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation
- Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.
- 02/01/2024
|
Compared to Estimates, Revvity (RVTY) Q4 Earnings: A Look at Key Metrics
- The headline numbers for Revvity (RVTY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/01/2024
|
Revvity, Inc. (RVTY) CEO Prahlad Singh presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
- Revvity, Inc. (RVTY) CEO Prahlad Singh presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
- 01/09/2024
|
Revvity (RVTY) Launches New Molecular Testing for Newborns
- Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.
- 12/01/2023
|
Revvity, Inc. (RVTY) Q3 2023 Earnings Call Transcript
- Revvity, Inc. (NYSE:RVTY ) Q3 2023 Earnings Conference Call October 30, 2023 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President Investor Relations Prahlad Singh - President and Chief Executive Officer Max Krakowiak - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citigroup Inc. Vijay Kumar - Evercore ISI Derik De Bruin - Bank of America Andrew Cooper - Raymond James Financial, Inc. Eve Burstein - Bernstein Research Jack Meehan - Nephron Research LLC Matthew Sykes - Goldman Sachs Joshua Waldman - Cleveland Research Company LLC Daniel Brennan - TD Cowen Luke Sergott - Barclays Plc Dan Leonard - UBS Group AG Daniel Arias - Stifel Financial Corp. Catherine Schulte - Robert W. Baird & Co. Operator Hello, and welcome to the Q3 2023 Revvity Earnings Conference Call.
- 11/05/2023
|
Why Revvity Stock Plunged Today
- Revvity announced weaker-than-expected third-quarter results and lowered its full-year outlook. CEO Prahlad Singh blamed today's "increasingly challenging end market environment," but insists the company is executing well nonetheless.
- 10/30/2023
|
Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View
- Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.
- 10/30/2023
|
Revvity tumbles on 3Q earnings miss; revised guidance in “increasingly challenging” environment
- Revvity Inc posted third-quarter revenue and earnings that fell short of market expectations and lowered its full-year guidance in what it described as an increasingly challenging end-market environment. The life sciences and diagnostics business reported a 5.8% decline in revenue to $670.7 million for the quarter to October 1, 2023, below the $695.4 million expected by the Street.
- 10/30/2023
|
Revvity Stock Tumbles 18% as Demand From Pharma and Biotech Customers Falls
- Revvity posts third-quarter earnings of $1.18 a share, 1 cent below estimates. Revenue of $670.7 million also came in below forecasts.
- 10/30/2023
|
Revvity's stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlook
- Shares of Revvity Inc. RVTY, -1.09% tumbled 14.2% toward a 3 1/2-year low Monday, enough to pace the S&P 500's SPX, +0.72% premarket decliners, after the health sciences company missed third-quarter earnings expectations and cut its full-year outlook citing “increased market uncertainty.” The company lowered its guidance ranges for 2023 adjusted earnings per share of $4.53 to $4.57 from $4.70 to $4.90 and for revenue to $2.72 billion to $2.74 billion from $2.80 billion to $2.85 billion.
- 10/30/2023
|
Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates
- Revvity (RVTY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.51 per share a year ago.
- 10/30/2023
|
Revvity cuts annual forecast on weak demand for diagnostics, contract research
- Revvity Inc cut its full-year sales and revenue forecasts after missing Wall Street estimates for third-quarter results, hurt by weak demand for its supplies to life science researchers and diagnostic solutions.
- 10/30/2023
|
Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow
- Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.
- 10/19/2023
|
Revvity (RVTY) Launches Three New Preclinical Research Systems
- Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.
- 09/06/2023
|
Revvity, Inc. (RVTY) Q2 2023 Earnings Call Transcript
- Revvity, Inc. (NYSE:RVTY ) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Stephen Willoughby - Vice President of Investor Relations Prahlad Singh - President and Chief Executive Officer Maxwell Krakowiak - Senior Vice President and Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Daniel Leonard - Credit Suisse Matthew Sykes - Goldman Sachs Vijay Kumar - Evercore Catherine Schulte - Baird Jack Meehan - Nephron Research Josh Waldman - Cleveland Research Andrew Cooper - Raymond James Dan Brennan - TD Cowen Derik De Bruin - Bank of America Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Elizabeth Garcia - UBS Operator Hello, and welcome to the Revvity Second Quarter 2023 Earnings Conference Call. My name is Alex, I'll be coordinating the call today.
- 08/06/2023
|
Compared to Estimates, Revvity (RVTY) Q2 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/01/2023
|
Revvity (RVTY) Q2 Earnings and Revenues Top Estimates
- Revvity (RVTY) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $2.32 per share a year ago.
- 08/01/2023
|
Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline
- Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2023
|
Revvity: New Name - But New Investment Outlook? Reiterate Buy
- Revvity, formerly PerkinElmer, has changed its name and made several updates to its investment outlook. It now has ~$2Bn to put to work following the sale of recent business units. I am still eyeing a price range of $137-145 following the latest investment updates.
- 07/18/2023
|
Revvity (RVTY) Launches Single Solution for Drug Development
- Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.
- 06/13/2023
|
Revvity (RVTY) Launches New System for Autoimmune Diagnostics
- Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.
- 06/06/2023
|
